Investing

Entrada Therapeutics : TRDA

TRDA

Stock Data

$14.50

$1.00 (7.41%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Entrada Therapeutics, based in Boston, Massachusetts, is a pioneering biotechnology firm focused on creating treatments for neuromuscular diseases. Using its innovative endosomal escape vehicle (EEV) platform, the company is developing a diverse portfolio that includes oligonucleotide, antibody, and enzyme-based therapies. Its leading candidates are aimed at tackling Duchenne muscular dystrophy and myotonic dystrophy type 1, with key projects like ENTR-601-44 and ENTR-601-45 in preclinical trials. Entrada also collaborates with Vertex Pharmaceuticals to advance its mission of bringing novel therapies to patients in need.

All Entrada Therapeutics Articles

1 Article

Trey Thoelcke | Dec 30, 2025 at 8:45 AM EST

The Biggest IPO of the Year Prompts Huge Insider Buy

Kodiak Sciences, Medline, and W.R. Berkley have seen some huge insider purchases, and there were some other notable insider purchases…